Lexicon Pharmaceuticals (LXRX, Financial) experienced a notable stock movement, with shares rising by 5.59%. The stock is currently priced at $1.70 per share, with a trading volume of 1.98697 million shares and a turnover rate of 0.55%. The stock's fluctuation is 4.35%.
Financial results show Lexicon achieved a revenue of $1.65 million. However, it reported a net loss of $53.43 million, with an earnings per share of -$0.17. The gross profit stood at $1.34 million, resulting in a price-to-earnings ratio of -2.16.
Analyst ratings on Lexicon Pharmaceuticals reveal that out of six institutions, 67% recommend buying, while 33% suggest holding, with no sell recommendations.
In the biotechnology sector, Lexicon's industry peers experienced a collective growth of 0.06%. Notable performers include Entero Therapeutics Inc., Lexaria Bioscience Corp C/Wts 14/01/2026 (To Pur Com), and Cue Biopharma, Inc. Active stocks include Aditxt, Inc., Seelos Therapeutics, Inc., and Theriva Biologics, Inc., with high turnover rates. Stocks with significant volatility include Nkgen Biotech Inc C/Wts 31/05/2028 (To Pur Com), Aditxt, Inc., and Geovax Labs Inc C/Wts 29/09/2025 (To Pur Com).
Lexicon Pharmaceuticals is a biopharmaceutical company engaged in discovering, developing, and commercializing pharmaceutical products for treating human diseases. Its drug candidates include oral small molecule LX9211 for neuropathic pain and sotagliflozin for heart failure and type 1 diabetes.
